Global Neuroendocrine Carcinoma Market Growth (Status and Outlook) 2025-2031

October 2025 | 102 pages | ID: GE545FBB7ED4EN
LP Information

Abstracts

According to this study, the global Neuroendocrine Carcinoma market size will reach US$ 1849 million by 2031.

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

With the continuous advancement of medical technology, more accurate and faster diagnostic methods may be available for the detection of neuroendocrine cancer in the future. This may include more advanced imaging techniques, biomarker testing, and more that can help detect disease earlier and develop treatment options.

LPI (LP Information)' newest research report, the “Neuroendocrine Carcinoma Industry Forecast” looks at past sales and reviews total world Neuroendocrine Carcinoma sales in 2024, providing a comprehensive analysis by region and market sector of projected Neuroendocrine Carcinoma sales for 2025 through 2031. With Neuroendocrine Carcinoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroendocrine Carcinoma industry.

This Insight Report provides a comprehensive analysis of the global Neuroendocrine Carcinoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Neuroendocrine Carcinoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuroendocrine Carcinoma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroendocrine Carcinoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroendocrine Carcinoma.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuroendocrine Carcinoma market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Chemotherapy
• Somatostatin Analogs
• Targeted Therapy

Segmentation by Application:

• Hospital
• Clinics
• Oncology Centres
• Ambulatory Surgery Centres

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Pfizer
• Novartis
• Chiasma
• Ipsen
• Abbvie
• Valeant
• Jubilant
• Teva
• F.Hoffmann-La Roche
• Advanced Accelerator
• Mateon
• Lexicon

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Neuroendocrine Carcinoma Market Size (2020-2031)
  2.1.2 Neuroendocrine Carcinoma Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Neuroendocrine Carcinoma by Country/Region (2020, 2024 & 2031)
2.2 Neuroendocrine Carcinoma Segment by Type
  2.2.1 Chemotherapy
  2.2.2 Somatostatin Analogs
  2.2.3 Targeted Therapy
2.3 Neuroendocrine Carcinoma Market Size by Type
  2.3.1 Neuroendocrine Carcinoma Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Neuroendocrine Carcinoma Market Size Market Share by Type (2020-2025)
2.4 Neuroendocrine Carcinoma Segment by Application
  2.4.1 Hospital
  2.4.2 Clinics
  2.4.3 Oncology Centres
  2.4.4 Ambulatory Surgery Centres
2.5 Neuroendocrine Carcinoma Market Size by Application
  2.5.1 Neuroendocrine Carcinoma Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Neuroendocrine Carcinoma Market Size Market Share by Application (2020-2025)

3 NEUROENDOCRINE CARCINOMA MARKET SIZE BY PLAYER

3.1 Neuroendocrine Carcinoma Market Size Market Share by Player
  3.1.1 Global Neuroendocrine Carcinoma Revenue by Player (2020-2025)
  3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Player (2020-2025)
3.2 Global Neuroendocrine Carcinoma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 NEUROENDOCRINE CARCINOMA BY REGION

4.1 Neuroendocrine Carcinoma Market Size by Region (2020-2025)
4.2 Global Neuroendocrine Carcinoma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neuroendocrine Carcinoma Market Size Growth (2020-2025)
4.4 APAC Neuroendocrine Carcinoma Market Size Growth (2020-2025)
4.5 Europe Neuroendocrine Carcinoma Market Size Growth (2020-2025)
4.6 Middle East & Africa Neuroendocrine Carcinoma Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Neuroendocrine Carcinoma Market Size by Country (2020-2025)
5.2 Americas Neuroendocrine Carcinoma Market Size by Type (2020-2025)
5.3 Americas Neuroendocrine Carcinoma Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Neuroendocrine Carcinoma Market Size by Region (2020-2025)
6.2 APAC Neuroendocrine Carcinoma Market Size by Type (2020-2025)
6.3 APAC Neuroendocrine Carcinoma Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Neuroendocrine Carcinoma Market Size by Country (2020-2025)
7.2 Europe Neuroendocrine Carcinoma Market Size by Type (2020-2025)
7.3 Europe Neuroendocrine Carcinoma Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neuroendocrine Carcinoma by Region (2020-2025)
8.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2020-2025)
8.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL NEUROENDOCRINE CARCINOMA MARKET FORECAST

10.1 Global Neuroendocrine Carcinoma Forecast by Region (2026-2031)
  10.1.1 Global Neuroendocrine Carcinoma Forecast by Region (2026-2031)
  10.1.2 Americas Neuroendocrine Carcinoma Forecast
  10.1.3 APAC Neuroendocrine Carcinoma Forecast
  10.1.4 Europe Neuroendocrine Carcinoma Forecast
  10.1.5 Middle East & Africa Neuroendocrine Carcinoma Forecast
10.2 Americas Neuroendocrine Carcinoma Forecast by Country (2026-2031)
  10.2.1 United States Market Neuroendocrine Carcinoma Forecast
  10.2.2 Canada Market Neuroendocrine Carcinoma Forecast
  10.2.3 Mexico Market Neuroendocrine Carcinoma Forecast
  10.2.4 Brazil Market Neuroendocrine Carcinoma Forecast
10.3 APAC Neuroendocrine Carcinoma Forecast by Region (2026-2031)
  10.3.1 China Neuroendocrine Carcinoma Market Forecast
  10.3.2 Japan Market Neuroendocrine Carcinoma Forecast
  10.3.3 Korea Market Neuroendocrine Carcinoma Forecast
  10.3.4 Southeast Asia Market Neuroendocrine Carcinoma Forecast
  10.3.5 India Market Neuroendocrine Carcinoma Forecast
  10.3.6 Australia Market Neuroendocrine Carcinoma Forecast
10.4 Europe Neuroendocrine Carcinoma Forecast by Country (2026-2031)
  10.4.1 Germany Market Neuroendocrine Carcinoma Forecast
  10.4.2 France Market Neuroendocrine Carcinoma Forecast
  10.4.3 UK Market Neuroendocrine Carcinoma Forecast
  10.4.4 Italy Market Neuroendocrine Carcinoma Forecast
  10.4.5 Russia Market Neuroendocrine Carcinoma Forecast
10.5 Middle East & Africa Neuroendocrine Carcinoma Forecast by Region (2026-2031)
  10.5.1 Egypt Market Neuroendocrine Carcinoma Forecast
  10.5.2 South Africa Market Neuroendocrine Carcinoma Forecast
  10.5.3 Israel Market Neuroendocrine Carcinoma Forecast
  10.5.4 Turkey Market Neuroendocrine Carcinoma Forecast
10.6 Global Neuroendocrine Carcinoma Forecast by Type (2026-2031)
10.7 Global Neuroendocrine Carcinoma Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Neuroendocrine Carcinoma Forecast

11 KEY PLAYERS ANALYSIS

11.1 Pfizer
  11.1.1 Pfizer Company Information
  11.1.2 Pfizer Neuroendocrine Carcinoma Product Offered
  11.1.3 Pfizer Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Pfizer Main Business Overview
  11.1.5 Pfizer Latest Developments
11.2 Novartis
  11.2.1 Novartis Company Information
  11.2.2 Novartis Neuroendocrine Carcinoma Product Offered
  11.2.3 Novartis Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Novartis Main Business Overview
  11.2.5 Novartis Latest Developments
11.3 Chiasma
  11.3.1 Chiasma Company Information
  11.3.2 Chiasma Neuroendocrine Carcinoma Product Offered
  11.3.3 Chiasma Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Chiasma Main Business Overview
  11.3.5 Chiasma Latest Developments
11.4 Ipsen
  11.4.1 Ipsen Company Information
  11.4.2 Ipsen Neuroendocrine Carcinoma Product Offered
  11.4.3 Ipsen Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Ipsen Main Business Overview
  11.4.5 Ipsen Latest Developments
11.5 Abbvie
  11.5.1 Abbvie Company Information
  11.5.2 Abbvie Neuroendocrine Carcinoma Product Offered
  11.5.3 Abbvie Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Abbvie Main Business Overview
  11.5.5 Abbvie Latest Developments
11.6 Valeant
  11.6.1 Valeant Company Information
  11.6.2 Valeant Neuroendocrine Carcinoma Product Offered
  11.6.3 Valeant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Valeant Main Business Overview
  11.6.5 Valeant Latest Developments
11.7 Jubilant
  11.7.1 Jubilant Company Information
  11.7.2 Jubilant Neuroendocrine Carcinoma Product Offered
  11.7.3 Jubilant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Jubilant Main Business Overview
  11.7.5 Jubilant Latest Developments
11.8 Teva
  11.8.1 Teva Company Information
  11.8.2 Teva Neuroendocrine Carcinoma Product Offered
  11.8.3 Teva Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Teva Main Business Overview
  11.8.5 Teva Latest Developments
11.9 F.Hoffmann-La Roche
  11.9.1 F.Hoffmann-La Roche Company Information
  11.9.2 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Offered
  11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 F.Hoffmann-La Roche Main Business Overview
  11.9.5 F.Hoffmann-La Roche Latest Developments
11.10 Advanced Accelerator
  11.10.1 Advanced Accelerator Company Information
  11.10.2 Advanced Accelerator Neuroendocrine Carcinoma Product Offered
  11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Advanced Accelerator Main Business Overview
  11.10.5 Advanced Accelerator Latest Developments
11.11 Mateon
  11.11.1 Mateon Company Information
  11.11.2 Mateon Neuroendocrine Carcinoma Product Offered
  11.11.3 Mateon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.11.4 Mateon Main Business Overview
  11.11.5 Mateon Latest Developments
11.12 Lexicon
  11.12.1 Lexicon Company Information
  11.12.2 Lexicon Neuroendocrine Carcinoma Product Offered
  11.12.3 Lexicon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2025)
  11.12.4 Lexicon Main Business Overview
  11.12.5 Lexicon Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Neuroendocrine Carcinoma Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Neuroendocrine Carcinoma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Somatostatin Analogs
Table 5. Major Players of Targeted Therapy
Table 6. Neuroendocrine Carcinoma Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Neuroendocrine Carcinoma Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Neuroendocrine Carcinoma Market Size Market Share by Type (2020-2025)
Table 9. Neuroendocrine Carcinoma Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Neuroendocrine Carcinoma Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Neuroendocrine Carcinoma Market Size Market Share by Application (2020-2025)
Table 12. Global Neuroendocrine Carcinoma Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Neuroendocrine Carcinoma Revenue Market Share by Player (2020-2025)
Table 14. Neuroendocrine Carcinoma Key Players Head office and Products Offered
Table 15. Neuroendocrine Carcinoma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Neuroendocrine Carcinoma Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Neuroendocrine Carcinoma Market Size Market Share by Region (2020-2025)
Table 20. Global Neuroendocrine Carcinoma Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Neuroendocrine Carcinoma Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Neuroendocrine Carcinoma Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Neuroendocrine Carcinoma Market Size Market Share by Country (2020-2025)
Table 24. Americas Neuroendocrine Carcinoma Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Neuroendocrine Carcinoma Market Size Market Share by Type (2020-2025)
Table 26. Americas Neuroendocrine Carcinoma Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Neuroendocrine Carcinoma Market Size Market Share by Application (2020-2025)
Table 28. APAC Neuroendocrine Carcinoma Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Neuroendocrine Carcinoma Market Size Market Share by Region (2020-2025)
Table 30. APAC Neuroendocrine Carcinoma Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Neuroendocrine Carcinoma Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Neuroendocrine Carcinoma Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Neuroendocrine Carcinoma Market Size Market Share by Country (2020-2025)
Table 34. Europe Neuroendocrine Carcinoma Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Neuroendocrine Carcinoma Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Neuroendocrine Carcinoma Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Neuroendocrine Carcinoma
Table 40. Key Market Challenges & Risks of Neuroendocrine Carcinoma
Table 41. Key Industry Trends of Neuroendocrine Carcinoma
Table 42. Global Neuroendocrine Carcinoma Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Neuroendocrine Carcinoma Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Neuroendocrine Carcinoma Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Neuroendocrine Carcinoma Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. Pfizer Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 47. Pfizer Neuroendocrine Carcinoma Product Offered
Table 48. Pfizer Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. Pfizer Main Business
Table 50. Pfizer Latest Developments
Table 51. Novartis Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 52. Novartis Neuroendocrine Carcinoma Product Offered
Table 53. Novartis Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. Novartis Main Business
Table 55. Novartis Latest Developments
Table 56. Chiasma Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 57. Chiasma Neuroendocrine Carcinoma Product Offered
Table 58. Chiasma Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Chiasma Main Business
Table 60. Chiasma Latest Developments
Table 61. Ipsen Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 62. Ipsen Neuroendocrine Carcinoma Product Offered
Table 63. Ipsen Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Ipsen Main Business
Table 65. Ipsen Latest Developments
Table 66. Abbvie Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 67. Abbvie Neuroendocrine Carcinoma Product Offered
Table 68. Abbvie Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Abbvie Main Business
Table 70. Abbvie Latest Developments
Table 71. Valeant Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 72. Valeant Neuroendocrine Carcinoma Product Offered
Table 73. Valeant Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Valeant Main Business
Table 75. Valeant Latest Developments
Table 76. Jubilant Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 77. Jubilant Neuroendocrine Carcinoma Product Offered
Table 78. Jubilant Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Jubilant Main Business
Table 80. Jubilant Latest Developments
Table 81. Teva Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 82. Teva Neuroendocrine Carcinoma Product Offered
Table 83. Teva Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. Teva Main Business
Table 85. Teva Latest Developments
Table 86. F.Hoffmann-La Roche Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 87. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Offered
Table 88. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 89. F.Hoffmann-La Roche Main Business
Table 90. F.Hoffmann-La Roche Latest Developments
Table 91. Advanced Accelerator Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 92. Advanced Accelerator Neuroendocrine Carcinoma Product Offered
Table 93. Advanced Accelerator Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 94. Advanced Accelerator Main Business
Table 95. Advanced Accelerator Latest Developments
Table 96. Mateon Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 97. Mateon Neuroendocrine Carcinoma Product Offered
Table 98. Mateon Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 99. Mateon Main Business
Table 100. Mateon Latest Developments
Table 101. Lexicon Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 102. Lexicon Neuroendocrine Carcinoma Product Offered
Table 103. Lexicon Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 104. Lexicon Main Business
Table 105. Lexicon Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Neuroendocrine Carcinoma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neuroendocrine Carcinoma Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Neuroendocrine Carcinoma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Neuroendocrine Carcinoma Sales Market Share by Country/Region (2024)
Figure 8. Neuroendocrine Carcinoma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Neuroendocrine Carcinoma Market Size Market Share by Type in 2024
Figure 10. Neuroendocrine Carcinoma in Hospital
Figure 11. Global Neuroendocrine Carcinoma Market: Hospital (2020-2025) & ($ millions)
Figure 12. Neuroendocrine Carcinoma in Clinics
Figure 13. Global Neuroendocrine Carcinoma Market: Clinics (2020-2025) & ($ millions)
Figure 14. Neuroendocrine Carcinoma in Oncology Centres
Figure 15. Global Neuroendocrine Carcinoma Market: Oncology Centres (2020-2025) & ($ millions)
Figure 16. Neuroendocrine Carcinoma in Ambulatory Surgery Centres
Figure 17. Global Neuroendocrine Carcinoma Market: Ambulatory Surgery Centres (2020-2025) & ($ millions)
Figure 18. Global Neuroendocrine Carcinoma Market Size Market Share by Application in 2024
Figure 19. Global Neuroendocrine Carcinoma Revenue Market Share by Player in 2024
Figure 20. Global Neuroendocrine Carcinoma Market Size Market Share by Region (2020-2025)
Figure 21. Americas Neuroendocrine Carcinoma Market Size 2020-2025 ($ millions)
Figure 22. APAC Neuroendocrine Carcinoma Market Size 2020-2025 ($ millions)
Figure 23. Europe Neuroendocrine Carcinoma Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Neuroendocrine Carcinoma Market Size 2020-2025 ($ millions)
Figure 25. Americas Neuroendocrine Carcinoma Value Market Share by Country in 2024
Figure 26. United States Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Neuroendocrine Carcinoma Market Size Market Share by Region in 2024
Figure 31. APAC Neuroendocrine Carcinoma Market Size Market Share by Type (2020-2025)
Figure 32. APAC Neuroendocrine Carcinoma Market Size Market Share by Application (2020-2025)
Figure 33. China Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 37. India Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Neuroendocrine Carcinoma Market Size Market Share by Country in 2024
Figure 40. Europe Neuroendocrine Carcinoma Market Size Market Share by Type (2020-2025)
Figure 41. Europe Neuroendocrine Carcinoma Market Size Market Share by Application (2020-2025)
Figure 42. Germany Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 43. France Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Neuroendocrine Carcinoma Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 56. APAC Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 57. Europe Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 59. United States Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 60. Canada Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 61. Mexico Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 62. Brazil Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 63. China Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 64. Japan Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 65. Korea Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 67. India Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 68. Australia Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 69. Germany Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 70. France Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 71. UK Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 72. Italy Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 73. Russia Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 74. Egypt Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 75. South Africa Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 76. Israel Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 77. Turkey Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)
Figure 78. Global Neuroendocrine Carcinoma Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Neuroendocrine Carcinoma Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Neuroendocrine Carcinoma Market Size 2026-2031 ($ millions)